onlineappendix.docVIP

Online Appendix The efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: Subgroup analysis across SCALE and phase 2 randomized trials J. Ard1, A. Cannon2, C.E. Lewis3, H. Lofton4, T. Vang Skj?th5, B. Stevenin6, X. Pi-Sunyer7on behalf of the Satiety and Clinical Adiposity – Liraglutide Evidence in in non-diabetic and diabetic individuals (SCALE) study groups. 1Wake Forest Baptist Medical Center, Winston-Salem, NC, USA 2Endocrine Metabolic Associates, 9501 Roosevelt Boulevard, Suite 400, Philadelphia, Pennsylvania 19144, USA 3Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA 4New York University School of Medicine, New York, NY, USA 5Novo Nordisk A/S, S?borg, Denmark 6Novo Nordisk Inc., Plainsboro, NJ, USA 7Columbia University, New York, NY, USA File S1 Supplemental Methods Summary details of each of the trials included in the analysis are shown in Table S1. The protocol for each trial was approved by local institutional review boards or ethics committees and all participants provided written informed consent before their respective trial-related activities were initiated. The trials were conducted at clinical research sites in accordance with the Declaration of Helsinki [1] and Good Clinical Practice guidelines [2]. Key exclusion criteria were type 1 or 2 diabetes (except for SCALE Diabetes, which specifically enrolled individuals with T2DM), the use of medications causing significant weight gain or loss, previous bariatric surgery, a history of chronic pancreatitis or idiopathic acute pancreatitis or of major depressive or other severe psychiatric disorders, family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma, and personal history of non-familial medullary thyroid carcinoma. Full inclusion and exclusion criteria for each of the trials have been published previously [3-7]. Participants received dietary counselling (either in a group o